Tech Company Financing Transactions
Deep Genomics Funding Round
Khosla Ventures and True Ventures participated in a $13 million Series B funding round for Deep Genomics. The round was announced on 9/27/2017.
Transaction Overview
Company Name
Announced On
9/27/2017
Transaction Type
Venture Equity
Amount
$13,000,000
Round
Series B
Investors
Khosla Ventures (Lead Investor)
Proceeds Purpose
In the next three years, Deep Genomics will use its platform to unlock new classes of anti-sense oligonucleotide therapies that were previously inaccessible, and advance them for clinical evaluation.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
661 University Ave. MaRS Centre 480
Toronto ON, M5G 1M1
Canada
Toronto ON, M5G 1M1
Canada
Phone
Undisclosed
Website
Email Address
Overview
Our scientific and technological roadmap is to build an integrated computational system that can learn, predict and interpret how genetic variation, whether natural or therapeutic, alters crucial cellular processes.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Brendan Frey
Chief Medical Officer
Ferd Massari
Vice President
Jeffrey Brown
VP - Bus. Development
Amanda Kay
VP - Human Resources
Hyla Pollak
VP - Operations
Matthew Cahill
VP - R & D
Troy Simpson
Browse more venture capital transactions:
Prev: 9/27/2017: DiscGenics venture capital transaction
Next: 9/27/2017: Transit venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to document every notable VC transaction. All VC database entries reported here come from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs